Andere Sprachen Camurus AB

Aktien

A2ABG7

SE0007692850

CAMX

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:32 31.05.2024			% 5 Tage	% 1. Jan.
581 ^SEK	+7,89 %		+3,66 %	+7,99 %

23.05.	Camurus' Medikament gegen seltene Wachstumsstörung in der EU zur Prüfung angenommen	MT
23.05.	Camurus erhält EMA-Zulassungsbescheid für Octreotid SC Depot (Cam2029) zur Behandlung von Akromegalie	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Camurus' Rare Growth Disorder Drug Accepted for Review in EU	23.05.
Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot for the Treatment of Acromegaly	23.05.
Transcript : Camurus AB, Q1 2024 Earnings Call, May 08, 2024	08.05.
Camurus AB Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Camurus AB Announces Board Resignations	02.04.
Camurus' New Drug Application for Acromegaly Treatment Accepted by US FDA	05.03.
Camurus AB Announces FDA Acceptance of NDA Submission for Oclaiz? for Treatment of Acromegaly	05.03.
Camurus AB Reports Earnings Results for the Full Year Ended December 31, 2023	15.02.
Transcript : Camurus AB, 2023 Earnings Call, Feb 15, 2024	15.02.
Camurus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15.02.
Camurus AB Provides Earnings Guidance for the Full Year 2024	15.02.
Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024	13.02.
Camurus AB Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease	08.02.
Camurus Submits US FDA New Drug Application for Hormonal Disorder Treatment	21.12.
Camurus AB Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly	21.12.
Camurus to Trade on Nasdaq Stockholm's Large Cap Segment	20.12.
Camurus Concludes Enrollment in Phase 3 Study of Neuroendocrine Tumors Vaccine	14.12.
Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors	14.12.
Transcript : Camurus AB, Q3 2023 Earnings Call, Nov 09, 2023	09.11.
Camurus AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Camurus AB

Aktien

A2ABG7

SE0007692850

CAMX

Andere Sprachen

Filter